For Q1 FY2026 (ended March 31, 2026), MoonLake Immunotherapeutics reported no revenue. Net loss was $69.7 million, a 74.5% increase from the prior year. Operating loss was $70.0 million, up 47.5%. Diluted EPS was -$0.98, a 55.6% decline. Cash and cash equivalents stood at $298.5 million, with total equity of $254.0 million and long-term debt of $99.0 million.
•No revenue generated in Q1 FY2026.
•Net loss widened to $69.7 million from $39.9 million a year ago.
•Operating loss increased to $70.0 million, reflecting higher R&D and SG&A expenses.
•Cash position of $298.5 million provides runway for ongoing clinical programs.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
MoonLake Immunotherapeutics, a clinical-stage biotechnology company focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology
For hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. Founded in 2021, the company is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases. Its lead candidate is Sonelokimab, a novel tri-specific Nanobody that inhibits both IL-17A and IL-17F, two key cytokines involved in inflammation. The company is investigating Sonelokimab for several conditions, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. By targeting these inflammatory pathways, MoonLake aims to provide new treatment options for patients with chronic immune-mediated diseases. The company operates in the biotechnology industry within the healthcare sector.
On which stock exchange is MoonLake Immunotherapeutics (MLTX) listed and in what currency?
MoonLake Immunotherapeutics is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol MLTX. The company's stock trades in US Dollars (USD). This listing provides the company with access to US capital markets and a broad investor base. As a clinical-stage biotechnology firm, its stock performance is closely tied to clinical trial results and regulatory developments for its lead product candidate, Sonelokimab. Investors should note that while the company is headquartered in Switzerland, its shares are traded in the United States, making it accessible to international investors.
What sector and industry does MoonLake Immunotherapeutics (MLTX) belong to?
MoonLake Immunotherapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies for diseases with high unmet medical needs. In MoonLake's case, the primary area of focus is inflammatory conditions affecting the skin and joints, such as psoriasis, psoriatic arthritis, and hidradenitis suppurativa. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Companies in this space often rely on successful clinical trials and regulatory approvals to bring new drugs to market.
Where is MoonLake Immunotherapeutics (MLTX) headquartered and what is its geographic focus?
MoonLake Immunotherapeutics is headquartered in Zug, Switzerland. The company was founded in 2021 and operates as a clinical-stage biotechnology firm. While its headquarters are in Switzerland, its stock is listed on the Nasdaq in the United States, indicating a global investor reach. The company's therapeutic focus is on inflammatory diseases that affect patients worldwide, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. Although the company is based in Europe, its clinical programs and potential market are global, targeting conditions that affect millions of people across different regions.
What is the business model of MoonLake Immunotherapeutics (MLTX) and how does it generate revenue?
As a clinical-stage biotechnology company, MoonLake Immunotherapeutics does not yet have any approved products or generate revenue from product sales. Its business model is centered on research and development of novel therapies, primarily Sonelokimab, a tri-specific Nanobody targeting IL-17A and IL-17F. The company's value creation depends on successfully advancing Sonelokimab through clinical trials, obtaining regulatory approvals, and eventually commercializing the drug either independently or through partnerships. MoonLake may also seek collaboration agreements with larger pharmaceutical companies to co-develop or license its assets, which could provide upfront payments, milestone payments, and royalties. Currently, the company is funded by investors and may raise additional capital through equity offerings or partnerships to support its R&D activities.